 Elizabeth Kessler
Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 14 | 2025 | 1043 | 2.940 |
Why?
| | Urinary Bladder Neoplasms | 7 | 2022 | 252 | 2.270 |
Why?
| | Carcinoma, Renal Cell | 8 | 2023 | 217 | 1.980 |
Why?
| | Kidney Neoplasms | 10 | 2023 | 403 | 1.940 |
Why?
| | Suicide, Assisted | 6 | 2024 | 26 | 1.780 |
Why?
| | Prostate-Specific Antigen | 3 | 2021 | 162 | 1.320 |
Why?
| | Antineoplastic Agents | 10 | 2025 | 2129 | 1.240 |
Why?
| | Physicians | 6 | 2024 | 910 | 0.990 |
Why?
| | Oncologists | 2 | 2024 | 38 | 0.930 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 1692 | 0.840 |
Why?
| | Patient Preference | 1 | 2025 | 191 | 0.800 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1079 | 0.650 |
Why?
| | Orchiectomy | 3 | 2016 | 71 | 0.640 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.600 |
Why?
| | Aged | 26 | 2025 | 23961 | 0.570 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 14 | 0.540 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2017 | 51 | 0.530 |
Why?
| | Plant Extracts | 1 | 2018 | 202 | 0.510 |
Why?
| | Prednisone | 1 | 2017 | 240 | 0.490 |
Why?
| | Capecitabine | 1 | 2015 | 45 | 0.490 |
Why?
| | Indazoles | 2 | 2014 | 69 | 0.490 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 30 | 0.490 |
Why?
| | Frailty | 1 | 2018 | 170 | 0.480 |
Why?
| | Imidazoles | 2 | 2014 | 238 | 0.460 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 57 | 0.460 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 81 | 0.450 |
Why?
| | Neoplasms | 6 | 2023 | 2671 | 0.450 |
Why?
| | Deoxycytidine | 1 | 2015 | 179 | 0.450 |
Why?
| | Spinal Neoplasms | 1 | 2014 | 32 | 0.450 |
Why?
| | Quinazolines | 1 | 2015 | 251 | 0.440 |
Why?
| | Anilides | 4 | 2022 | 73 | 0.440 |
Why?
| | Piperidines | 1 | 2015 | 206 | 0.430 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 110 | 0.420 |
Why?
| | Humans | 54 | 2025 | 137585 | 0.420 |
Why?
| | Neoplasm Metastasis | 5 | 2020 | 658 | 0.420 |
Why?
| | Immunotherapy | 1 | 2018 | 641 | 0.410 |
Why?
| | Canada | 5 | 2023 | 418 | 0.360 |
Why?
| | Male | 30 | 2025 | 67762 | 0.360 |
Why?
| | Geriatric Assessment | 4 | 2021 | 224 | 0.340 |
Why?
| | Pyridines | 4 | 2022 | 506 | 0.340 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 916 | 0.340 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7635 | 0.330 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 683 | 0.320 |
Why?
| | Surveys and Questionnaires | 9 | 2025 | 5778 | 0.320 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 77 | 0.310 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 655 | 0.310 |
Why?
| | Aging | 2 | 2018 | 1864 | 0.300 |
Why?
| | Androgen Antagonists | 3 | 2020 | 82 | 0.290 |
Why?
| | Caregivers | 2 | 2023 | 877 | 0.290 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 404 | 0.280 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 938 | 0.280 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1389 | 0.270 |
Why?
| | Middle Aged | 16 | 2025 | 33479 | 0.270 |
Why?
| | Communication | 2 | 2024 | 879 | 0.260 |
Why?
| | Urothelium | 3 | 2019 | 37 | 0.260 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 510 | 0.250 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2019 | 71 | 0.250 |
Why?
| | Stress, Psychological | 1 | 2014 | 1100 | 0.250 |
Why?
| | Treatment Outcome | 7 | 2019 | 10811 | 0.240 |
Why?
| | Penile Neoplasms | 1 | 2023 | 7 | 0.210 |
Why?
| | Pilot Projects | 5 | 2023 | 1710 | 0.210 |
Why?
| | Subacute Care | 1 | 2024 | 79 | 0.210 |
Why?
| | Terminally Ill | 1 | 2023 | 37 | 0.200 |
Why?
| | Administration, Oral | 1 | 2025 | 816 | 0.200 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 411 | 0.200 |
Why?
| | Bone Neoplasms | 2 | 2015 | 247 | 0.200 |
Why?
| | Skilled Nursing Facilities | 1 | 2024 | 141 | 0.200 |
Why?
| | Quality of Life | 4 | 2022 | 2892 | 0.190 |
Why?
| | Medical Oncology | 2 | 2021 | 289 | 0.190 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 36 | 0.180 |
Why?
| | Female | 17 | 2024 | 73304 | 0.180 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5472 | 0.180 |
Why?
| | Vasculitis | 1 | 2021 | 66 | 0.180 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2526 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 190 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 242 | 0.170 |
Why?
| | Adult | 11 | 2025 | 37929 | 0.170 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.170 |
Why?
| | Ureteral Neoplasms | 1 | 2019 | 1 | 0.160 |
Why?
| | Nephroureterectomy | 1 | 2019 | 2 | 0.160 |
Why?
| | Biopsy | 2 | 2021 | 1129 | 0.160 |
Why?
| | Hospice Care | 1 | 2022 | 202 | 0.160 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 548 | 0.160 |
Why?
| | Physical Examination | 1 | 2020 | 241 | 0.150 |
Why?
| | Palliative Care | 3 | 2024 | 758 | 0.150 |
Why?
| | Rheumatology | 1 | 2020 | 118 | 0.150 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 15 | 0.150 |
Why?
| | United States | 6 | 2025 | 14841 | 0.150 |
Why?
| | Colorado | 3 | 2024 | 4565 | 0.150 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 52 | 0.150 |
Why?
| | Patient Selection | 2 | 2020 | 696 | 0.140 |
Why?
| | Frail Elderly | 1 | 2018 | 131 | 0.140 |
Why?
| | Patient Discharge | 1 | 2024 | 897 | 0.140 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1171 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2018 | 86 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 804 | 0.140 |
Why?
| | Checklist | 1 | 2018 | 93 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 13 | 0.130 |
Why?
| | Prognosis | 4 | 2023 | 4030 | 0.130 |
Why?
| | Cancer Survivors | 1 | 2022 | 285 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.130 |
Why?
| | Taxoids | 1 | 2017 | 102 | 0.130 |
Why?
| | Age Factors | 3 | 2018 | 3295 | 0.130 |
Why?
| | Documentation | 1 | 2018 | 194 | 0.130 |
Why?
| | Mass Screening | 2 | 2021 | 1287 | 0.120 |
Why?
| | Cisplatin | 1 | 2018 | 320 | 0.120 |
Why?
| | Nutritional Status | 1 | 2018 | 350 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 322 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2021 | 234 | 0.120 |
Why?
| | Radiation Tolerance | 1 | 2015 | 96 | 0.110 |
Why?
| | Decision Making | 1 | 2022 | 900 | 0.110 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 50 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 155 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 806 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 8 | 0.110 |
Why?
| | Demography | 1 | 2014 | 291 | 0.100 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 17 | 0.100 |
Why?
| | Risk Assessment | 2 | 2023 | 3457 | 0.100 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 352 | 0.100 |
Why?
| | Feasibility Studies | 3 | 2023 | 956 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 229 | 0.100 |
Why?
| | Energy Metabolism | 1 | 2018 | 922 | 0.100 |
Why?
| | Pediatrics | 1 | 2020 | 1101 | 0.100 |
Why?
| | Clinical Competence | 1 | 2020 | 1118 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 267 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 547 | 0.090 |
Why?
| | Bone Diseases | 1 | 2012 | 62 | 0.090 |
Why?
| | Needs Assessment | 1 | 2014 | 376 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 822 | 0.090 |
Why?
| | Radiosurgery | 1 | 2015 | 344 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Health Personnel | 1 | 2018 | 710 | 0.090 |
Why?
| | Drugs, Investigational | 1 | 2011 | 33 | 0.090 |
Why?
| | Telemedicine | 1 | 2020 | 862 | 0.090 |
Why?
| | Urinary Bladder | 1 | 2013 | 183 | 0.090 |
Why?
| | Sarcoma | 1 | 2013 | 188 | 0.090 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2012 | 212 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1430 | 0.090 |
Why?
| | Pyrimidines | 1 | 2014 | 470 | 0.090 |
Why?
| | Disease Progression | 1 | 2018 | 2757 | 0.090 |
Why?
| | Sulfonamides | 1 | 2014 | 513 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1587 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 665 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 434 | 0.080 |
Why?
| | B7-H1 Antigen | 2 | 2022 | 217 | 0.080 |
Why?
| | Quality Improvement | 1 | 2018 | 1178 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 528 | 0.080 |
Why?
| | Survival Rate | 3 | 2019 | 1972 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 1325 | 0.070 |
Why?
| | Nephrectomy | 2 | 2018 | 169 | 0.060 |
Why?
| | Cohort Studies | 1 | 2015 | 5742 | 0.060 |
Why?
| | Conscience | 1 | 2024 | 7 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 10388 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2023 | 15657 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 410 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 113 | 0.050 |
Why?
| | Morals | 1 | 2023 | 82 | 0.050 |
Why?
| | Telephone | 1 | 2023 | 173 | 0.050 |
Why?
| | Young Adult | 4 | 2023 | 13209 | 0.050 |
Why?
| | SEER Program | 1 | 2023 | 227 | 0.050 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 20 | 0.050 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 34 | 0.050 |
Why?
| | Fatigue | 1 | 2023 | 329 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 73 | 0.040 |
Why?
| | Prostate | 1 | 2022 | 175 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5131 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 382 | 0.040 |
Why?
| | Europe | 1 | 2020 | 414 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1050 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 691 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 307 | 0.040 |
Why?
| | Delphi Technique | 1 | 2020 | 280 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 258 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 493 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 686 | 0.040 |
Why?
| | Pain | 1 | 2023 | 756 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1266 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 786 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 49 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 683 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 416 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 785 | 0.030 |
Why?
| | Adolescent | 3 | 2023 | 21513 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1153 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 130 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 142 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3566 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 78 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 64 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 2085 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 951 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2013 | 150 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.030 |
Why?
| | Keratins | 1 | 2013 | 173 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 305 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 193 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 120 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 390 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2013 | 389 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 124 | 0.020 |
Why?
| | Animals | 4 | 2017 | 36940 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1357 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 3958 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 872 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 614 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1738 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2691 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1916 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2057 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2167 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6828 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1313 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7604 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 6079 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1276 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 6763 | 0.020 |
Why?
| | Mice | 2 | 2013 | 17787 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3284 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2475 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3412 | 0.010 |
Why?
| | Child | 1 | 2023 | 21935 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4295 | 0.010 |
Why?
|
|
Kessler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|